基于雷贝拉唑四联疗法初始治疗胃炎和消化性溃疡患者幽门螺杆菌感染的效果

Effect of Rabeprazole Quadruple Therapy on HP Infection in Patients with Gastritis and Peptic Ulcer

目的探讨雷贝拉唑四联疗法初始治疗胃炎和消化性溃疡患者幽门螺杆菌(Hp)感染的效果。方法选取2016年2月至2018年2月期间本院收治的48例胃炎和消化性溃疡患者,采取随机数字表法将其分为对照组和观察组,每组24例。对照组采取三联疗法进行治疗,观察组采取雷贝拉唑四联疗法进行治疗。观察两组患者Hp根除率、Hp再感染率、溃疡愈合情况、症状消失时间及疼痛消失时间。结果相较于对照组,观察组Hp根除率和溃疡愈合率更高,而Hp再感染率更低,差异具有统计学意义(P<0.05);症状消失时间及疼痛消失时间对比,观察组明显比对照组短,差异具有统计学意义(P<0.05)。结论采取雷贝拉唑四联疗法初始治疗胃炎和消化性溃疡患者Hp感染能有效根除Hp,减少再感染率,缩短患者恢复时间,值得临床推广应用。

Objective To investigate the effect of rabeprazole quadruple therapy in the initial treatment of Hp infection in patients with gastritis and peptic ulcer. Methods 48 patients with gastritis and peptic ulcer admitted to our hospital from February 2016 to February 2018 were randomly divided into control group and observation group with 24 cases in each group. The control group was treated with triple therapy, while the observation group was treated with rabeprazole quadruple therapy. The eradication of Hp, reinfection of Hp, ulcer healing, ulcer recurrence, symptoms disappearance time and pain disappearance time of the two groups were observed. Results Compared with the control group, the Hp eradication rate and ulcer healing rate in the observation group were higher, while the reinfection rate of Hp and ulcer recurrence rate were lower, the difference was statistically significant(P<0.05);the disappearance time of symptoms and pain in the observation group was significantly shorter than that in the control group, the difference was statistically significant(P<0.05). Conclusion Rabeprazole quadruple therapy for Hp infection in patients with gastritis and peptic ulcer can effectively eradicate Hp, reduce recurrence rate and shorten recovery time, which is worthy of clinical application.